Clinical Trials Logo

Clinical Trial Summary

Microphthalmia transcription factor (MiT) family translocation renal cell carcinomas (TRCC) are rare subtypes of kidney cancers, which often arise in children and young adults. TRCC are characterized by translocations affecting transcription factors: Transcription Factor Binding To Immunoglobulin Heavy Constant Mu Enhancer 3 (TFE3) and Transcription Factor EB (TFEB). Little is known about TRCC molecular heterogeneity, in particular their transcriptomic and epigenetic subtype classification. Clinical behavior of TRCC is varying with age and Tumor, Node, Metastasis (TNM) stage. However, the biological basis of this aggressiveness is poorly understood. PURPOSE: The primary goal of this study is to decipher specific alterations in aggressive TRCC, defined as cases with metastatic dissemination at diagnosis. To tackle this problem, a retrospective cohort of TRCC cases in children and young adults will be created. We will then perform integrative comprehensive multi-omics analysis of these tumors to identify genetic, epigenetic and immune biomarkers associated with metastatic behavior in a training and validation datasets. Comparison of the multi-omics data will be compared to other type of rare Kidney tumors as well as clear-cell renal cell carcinomas


Clinical Trial Description

This retrospective cohort study aims to allow tumor collection of TRCC from three different networks: the French research network in renal cancer (UroCCR), the International Society of Paediatric Oncology (SIOP) database and the network for rare renal carcinomas (CARARE). Those samples will be divided in training and validation datasets. We will also collect samples from patients with other rare kidney cancers and clear-cell renal cell carcinomas allowing comparisons of similarity and differences between these tumors. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05456074
Study type Observational
Source Institut de cancérologie Strasbourg Europe
Contact Valérie SARTORI
Phone 368767223
Email v.sartori@icans.eu
Status Not yet recruiting
Phase
Start date January 25, 2023
Completion date January 25, 2026

See also
  Status Clinical Trial Phase
Recruiting NCT04718584 - the Efficacy and Safety of LDP in Patients With Urinary and Male Genital Tumors Phase 2
Recruiting NCT03114826 - Study of the Impact of VEGF Polymorphism on the Development of Renal Carcinoma in Renal Transplant Patients N/A
Recruiting NCT02928692 - Minocycline Attenuate Postoperative Cognitive Dysfunction and Delirium Phase 3
Recruiting NCT03475953 - A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors Phase 1/Phase 2
Recruiting NCT03638206 - Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies Phase 1/Phase 2
Recruiting NCT03786796 - Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations Phase 2
Completed NCT03064308 - The Assessment of the Feasibility of a Home Based Exercise Programme in the Older Patient Following Major Surgery N/A
Not yet recruiting NCT06318871 - Memory-like Natural Killer (NK) Cell Therapy With N-803 in Patients With Renal Cell Carcinoma or Urothelial Carcinoma Early Phase 1
Recruiting NCT06290427 - Comparison of Outcomes of Multiple Platforms for Assisted Robotic-Kidney (COMPAR-K) N/A
Withdrawn NCT02370342 - Robot-Assisted Ultrasound for Thermal Ablative Therapy in Treating Patients With Small Kidney Masses Undergoing Surgery N/A
Recruiting NCT04773951 - A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors Phase 1